<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04918225</url>
  </required_header>
  <id_info>
    <org_study_id>35RC20_9751_MAP-MS</org_study_id>
    <nct_id>NCT04918225</nct_id>
  </id_info>
  <brief_title>Motor Asymmetry in Progressive Multiple Sclerosis Patients</brief_title>
  <acronym>MAP-MS</acronym>
  <official_title>Motor Asymmetry in Progressive Multiple Sclerosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Project Rational&#xD;
&#xD;
      A better understanding of the causes of physical disability is an important unmet need in&#xD;
      progressive Multiple Sclerosis patients. Progressive Multiple Sclerosis patients most often&#xD;
      present a worsening pyramidal syndrome of lower and, to a lesser extent, upper limbs (Lublin&#xD;
      et al., 2014) suggesting a strong corticospinal tract involvement. The systematic high&#xD;
      resolution Magnetic Resonance Imaging exploration of lesions location and severity, as well&#xD;
      as extra-lesional tissue, on pan-medullar and encephalic motor tracts offers the opportunity&#xD;
      to better understand the pathological mechanism associated with motor impairment.&#xD;
&#xD;
      Scientific aims&#xD;
&#xD;
      This project will follow a twofold approach. First, the investigators will consider an&#xD;
      &quot;inter-patient&quot; approach where independent and absolute Magnetic Resonance metrics for each&#xD;
      limb will be related to disability. Second, the investigators will consider an&#xD;
      &quot;intra-patient&quot; approach (i.e. comparing differences of Magnetic Resonance metric and of&#xD;
      clinical score from the left and the right side in the same patient). For this purpose,&#xD;
      progressive Multiple Sclerosis patients with asymmetric motor impairment will be studied.&#xD;
      Confronting clinical and Magnetic Resonance Imaging metric value asymmetries indeed offers&#xD;
      the unique opportunity to free oneself from many confounding factors such as genetics, age,&#xD;
      duration of disease evolution, acquisition bias, etc. These two approaches will allow us to&#xD;
      precisely study the impact of local factors such as Multiple Sclerosis lesions located on&#xD;
      motor tracts on motor disability.&#xD;
&#xD;
      Methodology&#xD;
&#xD;
      The investigators propose an observational multicenter cross-sectional and prognostic study.&#xD;
      This study will involve two French centers (Rennes, Marseille) and will include a total of 40&#xD;
      progressive Multiple Sclerosis patients with an asymmetrical motor deficit. Twenty sex and&#xD;
      age matched controls will be needed to calibrate quantitative Magnetic Resonance imaging&#xD;
      (magnetization transfer ratio). Encephalic and pan medullar structural and quantitative&#xD;
      Magnetic Resonance images will be acquired at inclusion and clinical follow-up examinations&#xD;
      will be performed at inclusion and 24 months. Detailed motor evaluation &quot;per limb&quot; will be&#xD;
      performed, including the motor American Society Injury. Association sub-score and upper and&#xD;
      lower limbs muscle strength measurements using a dynamometer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 3, 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>link between focal and diffuse damage in motor tract</measure>
    <time_frame>Baseline</time_frame>
    <description>link between focal and diffuse damage in motor tract per side and it functional consequences per limb assessed clinically at baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Link between the asymmetry of functional motor impairment and the asymmetry of structural damage on the motor pathways</measure>
    <time_frame>Baseline</time_frame>
    <description>To study the link between the asymmetry of functional motor impairment and the asymmetry of structural damage on the motor pathways (intra-patient assessment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prognostic value of motor tract focal and diffuse damage on clinical scores variations</measure>
    <time_frame>24 months</time_frame>
    <description>To study the prognostic value of motor tract focal and diffuse damage on clinical scores variations at 2 years</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Multiple Sclerosis, Primary Progressive</condition>
  <condition>Multiple Sclerosis, Secondary Progressive</condition>
  <arm_group>
    <arm_group_label>Progressive Multiple Sclerosis patients</arm_group_label>
    <description>Progressive Multiple Sclerosis patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <description>Healthy Volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Encephalic (about 30 minutes*)&#xD;
lesion location assessment: 3D FLAIR, 3DT1, 3DT2 (standard OFSEP protocol)&#xD;
lesion severity assessment: Axial magnetization transfer imaging (mt0, mt1)&#xD;
tract location assessment: 30 directions diffusion imaging (standard OFSEP protocol)&#xD;
B0 and B1 mapping to correct for B0 and B1 inhomogeneities&#xD;
● Spinal cord (about 50 minutes*)&#xD;
lesion location assessment: cervical and thoracic sagittal T2 TSE (0.7x0.7x2.5mm3), axial cervical MEDIC T2* (0.7x0.7x3mm3), axial thoracic T2 (0.5x0.5x3mm3)&#xD;
lesion severity assessment: Axial magnetization transfer imaging (mt0, mt1, 0.7x0.7x3mm3) on the cervical cord and on the thoracic cord&#xD;
tract location assessment: performed from registration on atlas&#xD;
B0 and B1 mapping to correct for B0 and B1 inhomogeneities</description>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_label>Progressive Multiple Sclerosis patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Neurological examination</intervention_name>
    <description>Global disability will be scored using the Expanded Disability Status Scale score</description>
    <arm_group_label>Progressive Multiple Sclerosis patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Multiple Sclerosis Functional Composite</intervention_name>
    <description>Walking disability will be scored using the 25-foot timed-walked test&#xD;
Arm disability will be scored using the nine-hole peg test</description>
    <arm_group_label>Progressive Multiple Sclerosis patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Physiotherapist examination</intervention_name>
    <description>American Society Injury. Association motor subscore for each limb&#xD;
The muscle strength using a dynamometer. Two muscle groups will be tested for the upper (elbow flexors and extensors) and lower limbs (hip flexors and ankle dorsiflexion).&#xD;
The Ashworth Scale and the Tardieu Scale to assess spasticity.</description>
    <arm_group_label>Progressive Multiple Sclerosis patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient population will consist of progressive Multiple Sclerosis patients (both Primary&#xD;
        Progressive Multiple Sclerosis and Secondary Progressive Multiple Sclerosis), a population&#xD;
        for whom a better understanding of the causes of disability is an unmet need.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        1. - Inclusion Criteria:&#xD;
&#xD;
             1.1/ Patients:&#xD;
&#xD;
               -  Aged between 18 and 60 years.&#xD;
&#xD;
               -  Primary Progressive Multiple Sclerosis or Secondary Progressive Multiple&#xD;
                  Sclerosis as defined by Mac Donald revised criteria in 2017.&#xD;
&#xD;
               -  Expanded Disability Status Scale lower or equal to 8.0, at inclusion.&#xD;
&#xD;
               -  asymmetric motor deficit. The motor deficit asymmetry will be defined by a&#xD;
                  difference of 3 or more at the American Society Injury. Association motor&#xD;
                  sub-score per limb between the right lower limb and the left lower limb.&#xD;
&#xD;
               -  No evidence of focal inflammatory activity for at least 3 years (no clinical&#xD;
                  relapse, no gadolinium enhancement on an Magnetic Resonance Imaging scan and no&#xD;
                  new T2 lesion)&#xD;
&#xD;
               -  Provided written informed consent according to the Institutional review board&#xD;
                  approval&#xD;
&#xD;
               -  Affiliated to the French healthcare system.&#xD;
&#xD;
             1.2 / Controls:&#xD;
&#xD;
               -  Aged between 18 and 60 years, sex and age matched with patients.&#xD;
&#xD;
               -  Provided written informed consent according to the Institutional review board&#xD;
                  approval&#xD;
&#xD;
               -  Affiliated to the French healthcare system.&#xD;
&#xD;
          2. - Non-inclusion criteria:&#xD;
&#xD;
        2.1 /Patients:&#xD;
&#xD;
          -  cerebellar Expanded Disability Status Scale sub score higher than pyramidal Expanded&#xD;
             Disability Status Scale sub score.&#xD;
&#xD;
          -  Relapse or corticosteroids in the 30 days preceding inclusion.&#xD;
&#xD;
          -  Other neurological diseases.&#xD;
&#xD;
          -  Lack of ability to understand the Institutional review board consent form.&#xD;
&#xD;
          -  Magnetic Resonance contraindications.&#xD;
&#xD;
          -  Pregnancy and breastfeeding.&#xD;
&#xD;
          -  Major persons subject to legal protection (legal safeguards,&#xD;
             guardianship,curatorship), persons deprived of their liberty&#xD;
&#xD;
        2.2 / Controls:&#xD;
&#xD;
          -  Personal history of central nervous related disease&#xD;
&#xD;
          -  Familial history of Multiple Sclerosis.&#xD;
&#xD;
          -  Personal history of spinal cord injury.&#xD;
&#xD;
          -  Personal history of spondylotic myelopathy.&#xD;
&#xD;
          -  Magnetic Resonance Imaging contraindication.&#xD;
&#xD;
          -  Lack of ability to understand the Institutional review board form.&#xD;
&#xD;
          -  Major persons subject to legal protection (legal safeguards, guardianship,&#xD;
             curatorship), persons deprived of their liberty&#xD;
&#xD;
          -  Pregnancy and breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Kerbrat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Rennes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Kerbrat, MD</last_name>
    <phone>+33(0)299287076</phone>
    <email>anne.kerbrat@chu-rennes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital de la Timone, AP-HM</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bertrand Audoin, MD</last_name>
      <phone>+33(0)4 91 38 59 39</phone>
      <email>bertrand.audoin@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Bertrand Audoin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Kerbrat, MD</last_name>
      <phone>+33(0)299287076</phone>
      <email>anne.kerbrat@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Anne Kerbrat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 2, 2021</study_first_submitted>
  <study_first_submitted_qc>June 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>motor disability, Magnetic Resonance Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

